IPO in October, 2018 (NASDAQ:PHAS).

PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) was founded to commercialize applications of elastin-like polypeptides (ELPs), whose properties give them utility in a variety of applications in human medicine, including production, purification, and delivery of protein and peptide therapeutics. The Company's lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.